Literature DB >> 23719311

Current and future trends in treatment of severe retinopathy of prematurity.

David K Wallace1, Katherine Y Wu.   

Abstract

Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23719311     DOI： 10.1016/j.clp.2013.02.005

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN： 0095-5108            Impact factor:   3.430


  9 in total

1.  Endothelial microRNA-150 is an intrinsic suppressor of pathologic ocular neovascularization.

Authors:  Chi-Hsiu Liu; Ye Sun; Jie Li; Yan Gong; Katherine T Tian; Lucy P Evans; Peyton C Morss; Thomas W Fredrick; Nicholas J Saba; Jing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-15       Impact factor: 11.205

2.  Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.

Authors:  Aslı Vural; Dilbade Yıldız Ekinci; Ismail Umut Onur; Gülsüm Oya Hergünsel; Fadime Ulviye Yiğit
Journal:  Int Ophthalmol       Date:  2019-01-02       Impact factor: 2.031

Review 3.  Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity.

Authors:  Hao Tan; Patricia Blasco; Tamorah Lewis; Susan Ostmo; Michael F Chiang; John Peter Campbell
Journal:  Surv Ophthalmol       Date:  2021-03-02       Impact factor: 6.197

Review 4.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Retinopathy of prematurity: preferred practice patterns among pediatric ophthalmologists.

Authors:  Samiksha Fouzdar Jain; Helen H Song; Shaza N Al-Holou; Linda A Morgan; Donny W Suh
Journal:  Clin Ophthalmol       Date:  2018-05-25

6.  Clinical Efficacy and Safety of Propranolol in the Prevention and Treatment of Retinopathy of Prematurity: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Haibo B Kong; Guoyuan Y Zheng; Baomei M He; Ying Zhang; Qin Zhou
Journal:  Front Pediatr       Date:  2021-02-10       Impact factor: 3.418

7.  Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy.

Authors:  Chi-Hsiu Liu; Zhongxiao Wang; Ye Sun; John Paul SanGiovanni; Jing Chen
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

8.  MicroRNA-18a-5p Administration Suppresses Retinal Neovascularization by Targeting FGF1 and HIF1A.

Authors:  Ji-Tian Guan; Xin-Xin Li; De-Wei Peng; Wen-Meng Zhang; Jia Qu; Fan Lu; Robert J D'Amato; Zai-Long Chi
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

Review 9.  MicroRNAs in Vascular Eye Diseases.

Authors:  Chi-Hsiu Liu; Shuo Huang; William R Britton; Jing Chen
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.